 | • レポートコード：MRC2-11QY12285 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は肥大型心筋症治療薬のグローバル市場について調査・分析したレポートです。種類別（カルシウムチャネル遮断薬、抗不整脈薬、ベータアドレナリン遮断薬、抗凝固薬、その他）市場規模、用途別（病院、クリニック、外来手術センター、学術・研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別肥大型心筋症治療薬の競争状況、市場シェア ・世界の肥大型心筋症治療薬市場：種類別市場規模 2015年-2020年（カルシウムチャネル遮断薬、抗不整脈薬、ベータアドレナリン遮断薬、抗凝固薬、その他） ・世界の肥大型心筋症治療薬市場：種類別市場規模予測 2021年-2026年（カルシウムチャネル遮断薬、抗不整脈薬、ベータアドレナリン遮断薬、抗凝固薬、その他） ・世界の肥大型心筋症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、外来手術センター、学術・研究機関） ・世界の肥大型心筋症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来手術センター、学術・研究機関） ・北米の肥大型心筋症治療薬市場分析：米国、カナダ ・ヨーロッパの肥大型心筋症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの肥大型心筋症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の肥大型心筋症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの肥大型心筋症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Merck、Pfizer、Sanofi、Gilead Sciences ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.
Demand for Hypertrophic Cardiomyopathy (HCM) therapeutics is expected to grow over the forecast period, owing to increasing prevalence of hypertrophic cardiomyopathy worldwide.
Market Analysis and Insights: Global Hypertrophic Cardiomyopathy Therapeutics Market
The global Hypertrophic Cardiomyopathy Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hypertrophic Cardiomyopathy Therapeutics Scope and Market Size
Hypertrophic Cardiomyopathy Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hypertrophic Cardiomyopathy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AstraZeneca
Merck
Pfizer
Sanofi
Gilead Sciences
…
Market segment by Type, the product can be split into
Calcium Channel Blockers
Antiarrhythmic Agents
Beta Adrenergic Blocking Agents
Anticoagulants
Others
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hypertrophic Cardiomyopathy Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Hypertrophic Cardiomyopathy Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Calcium Channel Blockers
1.4.3 Antiarrhythmic Agents
1.4.4 Beta Adrenergic Blocking Agents
1.4.5 Anticoagulants
1.4.6 Others
1.5 Market by Application
1.5.1 Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Academic and Research Organizations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hypertrophic Cardiomyopathy Therapeutics Market Perspective (2015-2026)
2.2 Global Hypertrophic Cardiomyopathy Therapeutics Growth Trends by Regions
2.2.1 Hypertrophic Cardiomyopathy Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hypertrophic Cardiomyopathy Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Hypertrophic Cardiomyopathy Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hypertrophic Cardiomyopathy Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Hypertrophic Cardiomyopathy Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hypertrophic Cardiomyopathy Therapeutics Players by Market Size
3.1.1 Global Top Hypertrophic Cardiomyopathy Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Hypertrophic Cardiomyopathy Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hypertrophic Cardiomyopathy Therapeutics Market Concentration Ratio
3.2.1 Global Hypertrophic Cardiomyopathy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hypertrophic Cardiomyopathy Therapeutics Revenue in 2019
3.3 Hypertrophic Cardiomyopathy Therapeutics Key Players Head office and Area Served
3.4 Key Players Hypertrophic Cardiomyopathy Therapeutics Product Solution and Service
3.5 Date of Enter into Hypertrophic Cardiomyopathy Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hypertrophic Cardiomyopathy Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Hypertrophic Cardiomyopathy Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
5.2 Global Hypertrophic Cardiomyopathy Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
6.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in North America (2019-2020)
6.3 North America Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
6.4 North America Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
7.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
7.4 Europe Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
8.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in China (2019-2020)
8.3 China Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
8.4 China Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
9.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
9.4 Japan Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
10.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
11.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in India (2019-2020)
11.3 India Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
11.4 India Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size (2015-2020)
12.2 Hypertrophic Cardiomyopathy Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Hypertrophic Cardiomyopathy Therapeutics Introduction
13.1.4 AstraZeneca Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Hypertrophic Cardiomyopathy Therapeutics Introduction
13.2.4 Merck Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Hypertrophic Cardiomyopathy Therapeutics Introduction
13.3.4 Pfizer Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Sanofi
13.4.1 Sanofi Company Details
13.4.2 Sanofi Business Overview
13.4.3 Sanofi Hypertrophic Cardiomyopathy Therapeutics Introduction
13.4.4 Sanofi Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020)
13.4.5 Sanofi Recent Development
13.5 Gilead Sciences
13.5.1 Gilead Sciences Company Details
13.5.2 Gilead Sciences Business Overview
13.5.3 Gilead Sciences Hypertrophic Cardiomyopathy Therapeutics Introduction
13.5.4 Gilead Sciences Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020)
13.5.5 Gilead Sciences Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hypertrophic Cardiomyopathy Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Hypertrophic Cardiomyopathy Therapeutics Revenue
Table 3. Ranking of Global Top Hypertrophic Cardiomyopathy Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hypertrophic Cardiomyopathy Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Calcium Channel Blockers
Table 6. Key Players of Antiarrhythmic Agents
Table 7. Key Players of Beta Adrenergic Blocking Agents
Table 8. Key Players of Anticoagulants
Table 9. Key Players of Others
Table 10. Global Hypertrophic Cardiomyopathy Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Hypertrophic Cardiomyopathy Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Hypertrophic Cardiomyopathy Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Hypertrophic Cardiomyopathy Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Hypertrophic Cardiomyopathy Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Hypertrophic Cardiomyopathy Therapeutics Players
Table 21. Global Hypertrophic Cardiomyopathy Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Hypertrophic Cardiomyopathy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypertrophic Cardiomyopathy Therapeutics as of 2019)
Table 24. Global Hypertrophic Cardiomyopathy Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Hypertrophic Cardiomyopathy Therapeutics Product Solution and Service
Table 27. Date of Enter into Hypertrophic Cardiomyopathy Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Hypertrophic Cardiomyopathy Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Hypertrophic Cardiomyopathy Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Hypertrophic Cardiomyopathy Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Hypertrophic Cardiomyopathy Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 37. North America Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 39. North America Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 43. Europe Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 49. China Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 51. China Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 55. Japan Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 67. India Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 69. India Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Hypertrophic Cardiomyopathy Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Hypertrophic Cardiomyopathy Therapeutics Market Share (2019-2020)
Table 73. Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Share by Application (2015-2020)
Table 77. AstraZeneca Company Details
Table 78. AstraZeneca Business Overview
Table 79. AstraZeneca Product
Table 80. AstraZeneca Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020) (Million US$)
Table 81. AstraZeneca Recent Development
Table 82. Merck Company Details
Table 83. Merck Business Overview
Table 84. Merck Product
Table 85. Merck Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020) (Million US$)
Table 86. Merck Recent Development
Table 87. Pfizer Company Details
Table 88. Pfizer Business Overview
Table 89. Pfizer Product
Table 90. Pfizer Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020) (Million US$)
Table 91. Pfizer Recent Development
Table 92. Sanofi Company Details
Table 93. Sanofi Business Overview
Table 94. Sanofi Product
Table 95. Sanofi Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020) (Million US$)
Table 96. Sanofi Recent Development
Table 97. Gilead Sciences Company Details
Table 98. Gilead Sciences Business Overview
Table 99. Gilead Sciences Product
Table 100. Gilead Sciences Revenue in Hypertrophic Cardiomyopathy Therapeutics Business (2015-2020) (Million US$)
Table 101. Gilead Sciences Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Calcium Channel Blockers Features
Figure 3. Antiarrhythmic Agents Features
Figure 4. Beta Adrenergic Blocking Agents Features
Figure 5. Anticoagulants Features
Figure 6. Others Features
Figure 7. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Academic and Research Organizations Case Studies
Figure 12. Hypertrophic Cardiomyopathy Therapeutics Report Years Considered
Figure 13. Global Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Hypertrophic Cardiomyopathy Therapeutics Market Share by Players in 2019
Figure 18. Global Top Hypertrophic Cardiomyopathy Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hypertrophic Cardiomyopathy Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Hypertrophic Cardiomyopathy Therapeutics Revenue in 2019
Figure 20. North America Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Hypertrophic Cardiomyopathy Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
肥大型心筋症（HCM）治療薬の世界市場（～2026年） Hypertrophic Cardiomyopathy (HCM) is a condition in which a portion of the heart becomes thickened without an obvious cause. This results in the heart being less able to pump blood effectively. Symptoms vary from none to feeling tired, leg swelling, and shortness of breath. It may also result in che…- 拡張型心筋症の世界市場（～2026年） Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of …
- 心筋症の世界市場（～2026年） Cardiomyopathy refers to diseases of the heart muscle The major factors that contributes in the growth of the market are advancement in understanding and managing cardiomyopathy and rise in incidences of congestive heart failure, coronary heart disease, and heart attack. Further, increasing trend of…
- 拡張型心筋症治療の世界市場（～2026年） Dilated Cardiomyopathy (DCM) is a condition in which heart's left ventricle, is enlarged and weakened and the ability to pump blood is decreased. The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awa…
- 強皮症診断・治療の世界市場（～2026年） Market Analysis and Insights: Global Scleroderma Diagnostics and Therapeutics Market The global Scleroderma Diagnostics and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Scleroderma Diagnostics and Thera…